A comparison of the effectiveness and cost of treatment for vertebral fractures in women

Rheumatology

Volumn 34, Issue 12, 1995, Pages 1167-1171

  Francis, R M ^a   Anderson, F H ^a   Torgerson, D J ^b  

^a FREEMAN HOSPITAL   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Calcitonin; Cost effectiveness; Etidronate; Hormone replacement therapy; Osteoporosis; Vertebral fracture

Indexed keywords

CALCITRIOL; CONJUGATED ESTROGEN; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ETIDRONIC ACID; PREMPAK; SALCATONIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG COST; FEMALE; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSDERMAL DRUG ADMINISTRATION; VERTEBRA FRACTURE; VERTEBRA MALFORMATION;

AGED; CALCITONIN; COST-BENEFIT ANALYSIS; ESTROGEN REPLACEMENT THERAPY; ETIDRONIC ACID; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; SPINAL FRACTURES;

EID: 0029583344     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/34.12.1167     Document Type: Article

References (23)

1. Melton LJ, Chrischilles EA, Cooper C, Lane AW, Riggs BL. Perspective: How many women have osteoporosis? J Bone Mineral Res 1992;7:1005-10.
2. Cooper C. Epidemiology and public health impact of osteoporosis. In: Reid DM, ed. Bailliere’s clinical rheumatology—osteoporosis. London: Bailliere Tindall, 1993:7:459-77.
3. Leidig G, Minne HW, Sauer P et al. A study of complaints and their relation to vertebral destruction in patients with osteoporosis. Bone Miner 1990;8:217-29.
4. Scane AC, Sutcliffe AM, Francis RM. The sequelae of vertebral crush fractures in men. Osteoporosis Int 1994;4:89-92.
5. Lufkin EG, Wahner HW, O’Fallon WM et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992;117:1-9.
6. Storm T, Thamsborg G, Steinich T, Genant HK, Sorensen OH. Elfect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322: 1265-71.
7. Watts NB, Harris ST, Genant HK et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73-9.
8. Rico H, Henandez ER, Revilla M, Gomez-Castresana F. Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome. Bone Miner 1992;16:131-8.
9. Riggs BL, Hodgson SF, O’Fallon WM et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990;322:802-9.
10. Kleerekoper M, Petersen EL, Nelson DA et al. A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporosis Int 1991;1: 155-61.
11. Riggs BL, Melton LJ III. The prevention and treatment of ostepporosis. N Engl J Med 1992;327:620-7.
12. Lindsay R. Prevention and treatment of osteoporosis. Lancet 1993;341:801-5.
13. Aloia JF, Vaswani A, Yeh JK, Ellis K, Yasumura S, Cohn SH. Calcitriol in the treatment of postmenopausal osteoporosis. Am J Med 1988;84:401-8.
14. Ott SM, Chesnut CH III. Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann Intern Med 1989;110:267-84.
15. Tilyard MW, Spears GFS, Thompson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 1992;326:357-62.
16. Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. Br Med J 1992;305:556-61.
17. McGuire A, Henderson J, Mooney G. The economics of health care. New York: Routledge and Kegan Paul, 1988.
18. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. 1994:Number 28.
19. Stevenson JC, Cust MP, Gangar KF, Hillard TC, Lees B, Whitehead ML Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 1990;336:265-9.
20. Ettinger B, Black DM, Nevitt MC et al. Contribution of vertebral deformities to chronic back pain and disability. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1992;7:449-56.
21. Harris ST, Watts NB, Jackson RD et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy. Am J Med 1993; 95:557-67.
22. Belchetz PE. Drug therapy: Hormonal treatment of postmenopausal women. N Engl J Med 1994;330: 1062-71.
23. National Osteoporosis Society. Priorities for prevention. Bath: National Osteoporosis Society, 1994.